A Phase 2 interventional study of Recurrence-directed therapy (RDT) and ELIGARD 22.5mg in Prostate Adenocarcinoma and Castration Sensitive Prostate Cancer, sponsored by Ontario Clinical Oncology Group (OCOG). Recruiting at 5 sites in Canada. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-13.
Sponsored by Ontario Clinical Oncology Group (OCOG) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 713 studies in Prostatic Neoplasms with a site in Canada — 119 open to participants now, 223 under way, 64 of them phase 3. Prostatic Neoplasms · Canada.
Among the 713 studies in Prostatic Neoplasms with a site in Canada, this one is the 256th largest by planned enrollment of the 636 interventional ones that give a count, is one of 29 that started in 2026, is one of 157 in phase 2, reaches primary completion later than 205 of the 222 other live ones, and was the 660th registered.
7,058 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.
Browse Prostatic Neoplasms studies →119 of the 713 studies in Prostatic Neoplasms with a site in Canada are open now. Recruiting first, the newest first:
University Health Network, Toronto · Sites in Canada
Ages 18+ · Men only
University Health Network, Toronto · Sites in Canada
Ages 18+ · Men only
AstraZeneca · Sites in Canada, United States, Austria and 18 more countries
Ages 18+ · Men only
GlaxoSmithKline · Sites in Canada, Australia, Japan and 1 more country
Ages 18+ · Men only
AHS Cancer Control Alberta · Sites in Canada
Ages 18+ · Men only
A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →
Of the 1,236 Prostatic Neoplasms studies recruiting now, 933 (75%) set no upper age limit and 77 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.
This study: 18 Years and older · male · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
713 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 88 · Phase 2 207 · Phase 3 190 · Phase 4 14
First in 1992; this study’s year is marked. 29 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 162 is above the median of 60 across 5,358 interventional studies indexed under Prostatic Neoplasms.
Median enrollment 100 across the 636 interventional studies, 130 across the 73 observational. Of the 423 that completed or were terminated, 130 (31%) have results posted.
This tab as a report to print or save as PDF → With an account.
225 of 713 have an industry lead sponsor. The 10 most frequent:
Ontario Clinical Oncology Group (OCOG) is the lead sponsor of 56 studies on the registry; 4 are open to participants now.
Ontario Clinical Oncology Group (OCOG) has 6 studies filed under Prostatic Neoplasms — fewer than ten, so there is no comparison to draw.
55 of the studies in Prostatic Neoplasms with a site in Canada that are under way reach primary completion within a year, 13 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05169112Phase 3Ottawa Hospital Research InstituteImpact of Hormonal Therapy on Prostate Cancer Recurrence After Radical Prostatectomy | 2026-11 |
| NCT03767244Phase 3Janssen Research & Development, LLCA Study of Apalutamide in Participants With High-Risk, Localized or Locally Advanced Prostate Cancer Who Are Candidates for Radical Prostatectomy | 2026-12-01 |
| NCT02446405Phase 3University of SydneyEnzalutamide in First Line Androgen Deprivation Therapy for Metastatic Prostate Cancer | 2026-12-31 |
| NCT00223171Phase 3Université de SherbrookeDuration of Androgen Blockade Combined with Pelvic Irradiation in Prostate Cancers | 2026-12-31 |
| NCT00223145Phase 3Abdenour NabidStudy on the Role of Hormonal Treatment for Two Dosage Levels of Prostate Radiation Therapy Versus Prostate Radiation Therapy Alone | 2026-12-31 |
Add all 55 to your calendar (.ics) → With an account.
Among the 713 studies in Prostatic Neoplasms with a site in Canada, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this study is to determine whether the addition of Androgen Deprivation Therapy (ADT) utilizing the study drug ELIGARD® to Recurrence- Directed Therapy (RDT) improves progression-free survival (PFS) compared to RDT alone in patients with early radio-recurrent oligo-metastatic castrate / hormone sensitive prostate cancer (romCSPC). Participants will be assessed at standard of care clinic visits every 3 months. The follow-up period is 36 months.
A multi-centre, open-label, phase II randomized clinical trial evaluating the addition of Androgen Deprivation Therapy (ADT) utilizing the study drug ELIGARD® compared to Recurrence Directed Therapy (RDT) alone in patients with previously localized prostate adenocarcinoma treated with definitive radiotherapy or with salvage radiotherapy after radical prostatectomy who experience biochemical recurrence and present with oligo-metastases (i.e., \< 5 sites of metastases) on conventional imaging. Eligible and consenting patents will be randomized in a 1:1 fashion to either RDT alone (standard arm) or RDT +ADT (ELIGARD®) x12 months (experimental arm). During treatment study participants will be assessed for disease progression, development of castrate resistant prostate cancer (CRPC), acute and late genitourinary (GU) and gastrointestinal (GI) radiotherapy toxicity, the occurrence of adverse events, initiation of tertiary therapy, overall survival and quality of life through the completion of participant questionnaires. Participants will be assessed at standard of care clinic visits every 3 months. The follow-up period is 36 months from the date of randomization. The planned sample size is 162 study participants.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Recurrent Oligo- CSPC, M0 on conventional imaging (bone scan and CT scan of chest/abdomen/pelvis) with ≤ 5 metastases cumulative on all imaging, including MRI and PSMA-PET.
Note: Patients with conventional imaging M1 oligometastatic CSPC, who have no more than 5 metastatic sites in all imaging modalities including MRI and PSMA-PET, will be accepted for study enrollment.
Biochemical recurrent prostate cancer with ONE of the following PSA recurrence definitions:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adjuvant and neoadjuvant
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Local, regional or distant oligometastatic RDT in addition to treatment with ADT for 12 months in the form of ELIGARD®.
Radiation: Recurrence-directed therapy (RDT) · Drug: ELIGARD 22.5mg
Local, regional, and distant oligometastatic RDT.
Radiation: Recurrence-directed therapy (RDT)
RDT options include radiotherapy or surgical resection.
ADT in the form of ELIGARD 22.5 mg every 3 months for a total of 12 months.
Composite progression free survival
Biochemical, radiological or clinical progression \[composite PFS (cPFS) event\]
Time frame: Time from randomization to the occurrence of composite PFS event occurring up to the 36 month follow-up.
Disease progression
Disease progression: time to biochemical progression (bPFS) (proportion of bPFS events); Disease progression: proportion of conventional-imaging based progression (rPFS) (proportion of rPFS events); Disease progression: proportion with eugonadal progression (egPFS)
Time frame: Time from date of randomization, until the date of progression or death occurring up to the 36 month follow-up.
Time to initiation of tertiary therapy;
Any non-protocol treatment given for prostate cancer after protocol-specified intervention.
Time frame: Time of initial therapy to 36 month follow-up.
Proportion of patients that develop castrate-resistant prostate cancer (CRPC)
Proportion of patients that develop castrate-resistant prostate cancer (CRPC)
Time frame: During the 36 month follow-up.
Overall survival.
Overall survival.
Time frame: During the 36 month follow-up.
Rate of early and late Grade 3 or higher GU and GI toxicity.
The rate of early and late Grade 3 or higher GU and GI toxicity will be assessed at baseline, 3, 6, 15 and 36 months. The CTCAEv.5.0 (\> Grade 3, GI and GU) toxicity rates will be reported.
Time frame: At 3, 6, 15 and 36 months.
Quality of life assessed by EORTC QLQ C30
Study participant reported quality of life utilizing the following measurement EORTC QLQ C30
Time frame: Completed by the study participant at scheduled follow-up visits (Months 3, 6, 15 and 36).
Quality of life assessed by EORTC QLQ PR25 questionnaire
Time frame: Completed by the study participant at scheduled follow-up visits (Months 3, 6, 15 and 36).
Quality of life assessed by EORTC QLQ PRT20 questionnaire
Time frame: Completed by the study participant at scheduled follow-up visits (Months 3, 6, 15 and 36).
Plan to share: Yes — A complete de-identified patient-level data set will be made available to academic affiliated researchers for the purpose of meta-analysis or a newly proposed study. Data will be made available following submission of a maximum 2-page proposal. The study Steering Committee will review and, if acceptable, provide approval of the request. A signed data sharing access/transfer agreement will be required between the requesting party and OCOG. Authorship of publications to include the name of the study Principal Investigator. The data will be provided as SAS datasets (as a CPT or XPT file). Any other format requests or additional statistical support may incur costs to the requestor. Data will become available 12 months after publication by the study Principal Investigator, of the initial study results
Supporting information: Analytic code
Time frame: Data will become available 12 months after publication by the study Principal Investigator, of the initial study results. Note: The timeframe may vary based on the journal and internal contractual obligations. The relevant timeframe should be adjusted accordingly to be study specific.
Access criteria: A complete de-identified patient-level data set will be made available to academic affiliated researchers for the purpose of meta-analysis or a newly proposed study. Data will be made available following submission of a maximum 2-page proposal. The study Steering Committee will review and, if acceptable, provide approval of the request. A signed data sharing access/transfer agreement will be required between the requesting party and OCOG. Data requests should be submitted to the OCOG Director.
Data sharing details ↗ · www.ocog.ca
No publications or documents are linked to this record.
Started May 2026 (actual). Primary completion is estimated for Apr 2031, 59 months after the start.
Of 613 non-industry phase 2 interventional studies under Prostatic Neoplasms, half reached primary completion within 57 months of starting (the median), counting those still running; a quarter within 38 and three quarters within 86. This study's planned 59 months is close to that.
Counting every sponsor, half of 727 studies reached it within 53 months; a quarter within 34 and three quarters within 80.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Luprolide acetate gel depot
Ontario Clinical Oncology Group (OCOG)